Skip to main content

David Johnson

Professor of Chemistry, Emeritus
David Johnson

David Johnson has been a member of the Geneseo faculty since 1991.

Office Hours

  • Monday  2:30 - 4:00

  • Tuesday  9:00 - 10:30

Curriculum Vitae


  • Ph.D. (Organic Chemistry) Montana State University

  • BS (Chemistry) Hamline University


  • Welch Post Doctoral Fellow, Trinity University, San Antonio, TX

  • Visiting Professor of Chemistry, Carleton College, Northfield, MN


  • Houser, K.R., Johnson, D.K. and Ishmael, F.T. "Anti-inflammatory Effects on Methoxyphenolic Compounds on Human Airway Cells" Journal of Inflammation, 2012, 9:6 (…)

  • Robert W. O'Donnell, David K. Johnson, Linda M. Ziegler Andrew J. DiMattina, Robert I. Stone, James A. Holland, ?Endothelial NADPH Oxidase: Mechanism of Activation by Low-Density Lipoprotein? Endothelium, 2003, 10, 291-297.

  • Johnson, D.K.; O?Donnell, R.W.; Schillinger, K.J.; Kwiat, D.K.; Hughes, C.C; McNamara, E.J.; Ishmael, F.; Hogg, M.G., Santhanam, L., Ziegler, L.M.; Chang, M. Dordick, J.S. and Holland, J.A. ?Metabolic Activation of an NADPH Oxidase Inhibitor: Apocynin, An o-Methoxy-4-Substituted Catechol? Endothelium, 2002, 9, 191-203.

  • Holland, J.A. and Johnson, D.K., Use of NADPH Oxidase Inhibitors for the Manufacture of a Medicament for Prevention of Atherosclerosis, European Patent 861070B1, 2000.

  • Holland, J.A.; Gross, R.A.; ODonnell, R.W.; Chang, M.-M.; Johnson, D.K.; and Zeigler, L.M., Low-Density Lipoprotein Induced Actin Cytoskeleton Reorganization in Endothelial Cells: Mechanisms of Action, Endothelium, 2001, 8, 117-135.

  • Holland, J.A.; O?Donnell, R.W.; Chang, M.; Johnson, D.K. and Ziegler, L.M., Endothelial Cell Oxidant Production: Effect of NADPH Oxidase Inhibitors, Endothelium, 2000, 7, 109-119.

  • Holland, J.A. and Johnson, D.K. , Prevention of Atherosclerosis Using NADPH Oxidase Inhibitors, United States Patent 5902831, 1999.

More About Me

Research Interests

My research is directed at understanding the molecular basis of NADPH oxidase inhibition by apocynin (4-hydroxy-3-methoxyacetophenone) and its derivatives. The activated NADPH oxidase complex produces reactive oxygen species which are involved in the early stage development of a series of inflammatory diseases such as atherosclerosis, diabetic retinopathy and asthma. A clearer understanding of this inhibition mechanism may lead to a novel therapy for diseases involving NADPH oxidase induced oxidative stress.

Additional Interests

  • The development of myleoperoxidase inhibitors to treat inflammatory diseases.
  • The utilization of NMR spectroscopy in undergraduate laboratories to study the stereochemistry of addition reactions.